HOE140 Icatibant
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Joint Disease
Conditions
Joint Disease
Trial Timeline
Feb 1, 2006 → Jul 1, 2007
NCT ID
NCT00303056About HOE140 Icatibant
HOE140 Icatibant is a phase 2 stage product being developed by Sanofi for Joint Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00303056. Target conditions include Joint Disease.
What happened to similar drugs?
1 of 2 similar drugs in Joint Disease were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00303056 | Phase 2 | Completed |
Competing Products
6 competing products in Joint Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine | SI-BONE | Approved | 29 |
| oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo | Johnson & Johnson | Phase 3 | 40 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 24 |
| etanercept + placebo | Pfizer | Phase 2 | 35 |
| VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN | Pfizer | Phase 2 | 31 |
| Methylprednisoloneacetate + Lidocaine | Lundbeck | Phase 2 | 32 |